Editas Medicine (EDIT) Current Deferred Revenue (2015 - 2025)

Editas Medicine (EDIT) has 11 years of Current Deferred Revenue data on file, last reported at $44.5 million in Q4 2025.

• Quarterly Current Deferred Revenue fell 26.34% year-over-year to $44.5 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $44.5 million (down 26.34% YoY) and the FY2025 annual result came in at $44.5 million, down 26.34% from the prior year.
• Current Deferred Revenue declined to $44.5 million in Q4 2025 per EDIT's latest filing, from $54.2 million in the prior quarter.
• Across five years, Current Deferred Revenue topped out at $89.4 million in Q1 2021 and bottomed at $2.0 million in Q1 2025.
• The 5-year median for Current Deferred Revenue is $54.2 million (2025), against an average of $43.9 million.
• The widest annual swing landed in 2023, when Current Deferred Revenue surged 1532.03%; it then slumped 97.1% in 2025.
• Tracing EDIT's Current Deferred Revenue over 5 years: stood at $72.2 million in 2021, then tumbled by 88.62% to $8.2 million in 2022, then jumped by 737.95% to $68.9 million in 2023, then declined by 12.29% to $60.4 million in 2024, then dropped by 26.34% to $44.5 million in 2025.
• Per Business Quant, the three latest EDIT Current Deferred Revenue figures stand at $44.5 million (Q4 2025), $54.2 million (Q3 2025), and $2.0 million (Q1 2025).

Peer Comparison